罕见病优先排序模型与景观分析

prioritization model andlandscape analysis Case Study| Rare disease prioritization model and landscape analysis Situation A global pharmaceutical company required anobjective assessment of multiple rare diseases toidentify the most promising indications in which todevelop preclinical candidate molecules. Approach Leveraging Citeline’s proprietary datasets, our Consulting & Analytics teamcreated a weighted prioritization model to assess each rare disease acrossmultiple areas―including unmet need, market competition, developmentfeasibility,and the client’s target product profile―to produce the finalranking and recommendation. Further insight into the highest-rankeddiseases was provided by a series of complementary disease landscapes. Case Study| Rare disease prioritization model and landscape analysis Solution Prioritization ModelCiteline created a weighted prioritization model to rank indications as the most attractive developmentopportunities for a set of preclinical assets. Ranking ModelThe client received an interactive Excel model, ranking multiple rare diseases as opportunities in which to pursue the development of itsportfolio of preclinical candidates. ParametersWeightings could be set by the user for four broad parameter groups and over 30 specificsub-parameters. Model OutputsModel outputs were illustrated using dynamic bubble plots and heat mapping to facilitate the interpretation of final scores. Impact We developed a rigorous prioritization model and complemented it with in-depthdisease analysis. The ranking not only highlighted the most promising indicationsfor preclinical candidate molecules but also provided actionable recommendationsto guide the client’s strategic decision-making. Armed with insightful intelligence,the client could confidently allocate resources and prioritize initiatives that alignedwithitsoverarching goals and objectives. Case Study| Rare disease prioritization model and landscape analysis Example Deliverables Future trends Near-term focus may be more heavily concentrated on treatment of CIPN, followed by prevention Case Study| Rare disease prioritization model and landscape analysis Value Subject-matter expertiseon a range of therapyareas to partner with you on your bespoke businessneeds Leveraging market-leadingproducts and real-world data (RWD)solutions Validating, benchmarking, andrefiningdata to assess feasibility Accurate and crediblerecommendationsyou can trust for successful outcomes 5Copyright © 2024 Citeline, a Norstella company. ( U nauthorized p h otocopying p rohibited).Leverage the Citeline Consulting & Analytics team to assess the rarediseases landscape, using our deep domain expertise and accessto extensive databases to compile a holistic view of the currentlandscape with state-of-the-art visualizations and insights. Citeline, aNorstellacompany, powers a full suite ofcomplementary business intelligence offerings to meet theevolving needs of life science professionals to accelerate theconnection of treatments to patients and patients to treatments.These patient-focused solutions and services deliver and analyzedata used to drive clinical, commercial,and regulatory-relateddecisions and create real-world opportunities for growth. Our global teams of analysts, journalists,and consultants keeptheir fingers on the pulse of the pharmaceutical, biomedicaland medtech industries, covering it all with expert insights: keydiseases, clinical trials, drug R&D and approvals, market forecasts,and more. For more information on one of the world’s most trustedlife science partners, visitCiteline.com